Skip to content
AnalystLens
In the record · 2016–202610-K1210-Q18-K401

JHX filed 12 annual reports (10-K), 1 quarterly reports (10-Q) and 401 current reports (8-K) between 2016 and 2026.

Summary

Summary of the 6-K filed March 20, 2026. Cited figures are marked; the original filing is the authoritative source.

This Form 6-K from James Hardie Industries plc (ticker JHX) filed March 20, 2026 contains no financial results or corporate announcements.

It consists of ASX-required notices: an Appendix 3G (notification of issue of unquoted equity securities) dated March 19, 2026, and nine Appendix 3Y change-of-director's-interest notices covering share issuances on March 13, 2026 under the James Hardie 2020 Non-Executive Director Equity Plan. The Appendix 3G reports 7,693 ordinary shares (JHXAM) issued on March 13, 2026 to eight key management personnel and non-executive directors, and lists post-issue unquoted securities including 149,732,160 JHXAM ordinary shares, 5,518,023 restricted stock units, and 269,221 options expiring November 3, 2027 at an exercise price of $33.05a. Quoted CHESS depositary interests (JHX) total 430,438,730 on issue.

The filing states the issuance was made under Listing Rule 7.2 exception 14, following a waiver from Listing Rule 2.4 granted by ASX on July 16, 2025. Each director's notice reports shares acquired on March 13, 2026 with no disposals, at the stated consideration in US dollars.

Individual holdings are small relative to total shares outstanding, and the filing contains no forward guidance, earnings data, or changes to capital structure beyond these routine director equity grants. The forward-looking statements section cautions readers about AZEK integration, AICF asbestos contributions, and other risks described in the company's Form 20-F filed May 20, 2025.

Key Highlights

  1. Filing consists of routine ASX disclosures: an Appendix 3G and nine Appendix 3Y director interest notices.
  2. 7,693 JHXAM ordinary shares issued on March 13, 2026 under the James Hardie 2020 Non-Executive Director Equity Plan.
  3. Eight directors and key management personnel each received between 566 and 1,776 ordinary shares, at consideration ranging from US$14,223.58 to US$44,630.88 per director.
  4. Post-issue unquoted securities total 149,732,160 JHXAM ordinary shares, 5,518,023 restricted stock units, and 269,221 options expiring November 3, 2027 at US$33.05.
  5. Quoted CHESS depositary interests (JHX) total 430,438,730 on issue after the issuance.
  6. Issuance relied on ASX Listing Rule 7.2 exception 14, following an ASX waiver from Listing Rule 2.4 granted July 16, 2025.
  7. No dispositions were reported, and no forward guidance, earnings, or capital-structure changes beyond these grants are disclosed.

Frequently Asked Questions

  1. Does this filing contain any financial results or guidance?

    No. The filing contains only ASX director-interest and unquoted-securities notices. It does not include earnings, revenue, or guidance figures.

  2. Why were shares issued to directors on March 13, 2026?

    The Appendix 3Y notices state the shares were issued pursuant to the James Hardie 2020 Non-Executive Director Equity Plan, with each director acquiring ordinary shares and disposing of none.

  3. How many shares did the directors receive in total?

    The Appendix 3G reports 7,693 JHXAM ordinary shares issued on March 13, 2026 to the eight named key management personnel and directors.

  4. Did any director sell shares?

    No. Each Appendix 3Y notice reports the number disposed as nil.

  5. What unquoted securities remain outstanding after the issuance?

    The filing lists 149,732,160 JHXAM ordinary shares, 5,518,023 restricted stock units, and 269,221 options expiring November 3, 2027 with an exercise price of US$33.05.